中枢神経系治療市場：疾患別、薬剤タイプ別、投与経路別、エンドユーザー別-2025～2030年の世界予測

中枢神経系治療市場の2023年の市場規模は1,338億3,000万米ドルで、2024年には1,431億1,000万米ドルに成長し、CAGRは7.24%、2030年には2,184億5,000万米ドルに達すると予測されています。

中枢神経系治療のセグメントは急速に進化しており、治療、診断、患者管理へのアプローチを再定義しています。近年、研究、技術、臨床手法の進歩は、複雑な神経疾患の治療において、より個別化された革新的な診療への道を切り開いてきました。多大な研究投資と疾患メカニズムに対する理解の深まりは、医療における長年の課題に対処する、より的を絞った治療法の開発を後押ししています。

また、臨床医や研究者が早期のバイオマーカーを同定し、病気の経過を正確に予測することを可能にする先進的診断ツールの統合や、新たなトランスレーショナル・リサーチの台頭が、この状況を特徴づけています。この変革の時代は、単に漸進的な改良にとどまらず、精密医療に重点を置いた中枢神経系疾患の管理方法のパラダイムシフトを意味しています。

前臨床と臨床研究の進展により、新たな分子標的の同定と検証が加速しています。その結果、利害関係者は現在、多様な患者集団における有効性と安全性を評価するための強化されたツールを備えており、治療法が有効であるだけでなく、個々のニーズにうまく適合したものであることを保証しています。この採用は、中枢神経系治療を世界的に変革しつつある多面的な開発を理解するための土台となります。

CNS治療の情勢を変える変革の波

近年の中枢神経系治療の動向は、医薬品開発における画期的なイノベーション、規制改革、戦略的な市場力学に後押しされ、変革の波が押し寄せています。先進的データ分析とゲノミクスの統合は、新規治療対象の同定を加速させ、かつては将来の可能性の領域としか考えられていなかった、より微妙な治療アプローチを可能にしました。

このセグメントの利害関係者は、臨床研究と現実のエビデンスの境界が曖昧になるにつれ、大きな変化を経験しています。この相乗効果により、学術機関、バイオテクノロジー企業、製薬会社が共同で、発見から患者への提供までのペースを速めるという協力的な環境が醸成されています。このようなパートナーシップは、有望な技術革新の市場投入までの時間を短縮するだけでなく、神経疾患への取り組みに新たな視点を産業に吹き込んでいます。

これと並行して、デジタルトランスフォーメーションは、創薬や患者モニタリングへの人工知能や機械学習技術の導入に拍車をかけています。この進化は、より正確な予測モデリングをサポートし、臨床検査デザインを強化し、患者層別化を最適化することで、最終的にはより効果的で安全な治療につながります。規制当局も世界的に進化しており、安全性と有効性が証明された新治療が迅速に臨床に組み込まれるよう、迅速なパスウェイと柔軟な枠組みを提供しています。

さらに、個別化医療の台頭は、従来の画一的な治療法から、より患者に特化した治療法へと急速にシフトしていることを裏付けています。こうした変革的な動向は、市場力学を再構築し、戦略を方向転換させ、次世代の中枢神経系治療に向けた強固な基盤を確立しつつあります。

市場戦略を形成する主要セグメンテーション洞察

市場セグメンテーションを詳細に調査することで、CNS治療の領域における戦略的意思決定を導く重要な洞察が明らかになります。障害による主要なセグメンテーション評価により、さまざまな神経疾患が明確なカテゴリーに層別化された市場の包括的な見解が得られます。市場はてんかん性疾患、神経変性疾患、疼痛管理、精神疾患に基づいて分析されています。てんかん性疾患では、てんかんと発作性疾患を区別するためにさらに焦点が絞られています。神経変性疾患のセグメントでは、アルツハイマー病、筋萎縮性側索硬化症、多発性硬化症、パーキンソン病に焦点が当てられています。同様に、疼痛管理は急性疼痛、慢性疼痛、神経障害性疼痛に分けられ、精神疾患には不安障害、双極性障害、うつ病、統合失調症が含まれます。

さらに薬剤タイプによるセグメンテーションにより、市場分析は生物製剤と低分子に分けられます。生物製剤の領域では、遺伝子治療、モノクローナル抗体、ペプチド、幹細胞治療まで調査が及んでおり、それぞれのサブカテゴリーに特有の機会と課題が明らかにされています。投与経路は、製品が注射剤、経口剤、経皮剤に分類されるもう一つの重要なセグメンテーション次元を形成しています。注射剤のカテゴリーでは、評価は筋肉内、静脈内、皮下にまで及び、患者のコンプライアンスと治療効果を最大化するために投与メカニズムが最適化されるようにします。

最後に、市場をエンドユーザー（病院、研究機関、専門クリニック）の視点から理解することで、潜在的な採用率や治療効果に関する貴重な視点が得られます。このように多様な競合要因によって全体像を把握することで、産業関係者はアプローチを調整し、リスクを軽減し、競争の激しい情勢の中で新たな機会を活かすことができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者の増加と神経変性疾患の蔓延
    • 神経疾患に関する調査に対する政府の取り組みと資金提供の実施
  • 抑制要因
    • 中枢神経系薬剤に関連する製品回収件数が増加
  • 機会
    • 神経変性疾患に対する遺伝子編集技術と幹細胞調査への投資
    • 革新的な医薬品製剤のためのナノ材料の潜在的な利用
  • 課題
    • 中枢神経系疾患の複雑さと血液脳関門の通過の難しさ
• 市場セグメンテーション分析
  • 疾患：てんかん疾患の有病率の増加と満たされていない医療ニーズの深刻化
  • 薬剤タイプ：特定の強力な治療のための革新的な生物製剤
  • 投与経路：長時間作用型の製剤のため、注射剤が好まれる
  • エンドユーザー：病院では即時介入のための中枢神経系治療の需要が高い
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 中枢神経系治療市場：疾患別

• イントロダクション
• てんかん疾患
  • てんかん
  • 発作性疾患
• 神経変性疾患
  • アルツハイマー病
  • 筋萎縮性側索硬化症
  • 多発性硬化症
  • パーキンソン病
• 疼痛管理
  • 急性疼痛
  • 慢性疼痛
  • 神経障害性疼痛
• 精神疾患
  • 不安障害
  • 双極性障害
  • うつ
  • 統合失調症

第7章 中枢神経系治療市場：薬剤タイプ別

• イントロダクション
• 生物製剤
  • 遺伝子治療
  • モノクローナル抗体
  • ペプチド
  • 幹細胞療法
• 小分子

第8章 中枢神経系治療市場：投与経路別

• イントロダクション
• 注射剤
  • 筋肉内
  • 静脈内
  • 皮下
• 経口
• 経皮

第9章 中枢神経系治療市場：エンドユーザー別

• イントロダクション
• 病院
• 研究機関
• 専門クリニック

第10章 南北アメリカの中枢神経系治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の中枢神経系治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの中枢神経系治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AC Immune SA
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics, Inc.
• Alkermes PLC
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• Cassava Sciences, Inc.
• Cipla Limited
• CNS Pharmaceuticals, Inc.
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Intra-Cellular Therapies, Inc.
• Ipsen S.A.
• Johnson & Johnson Services, Inc.
• Lupin Limited
• MapLight Therapeutics, Inc.
• Merck KGaA
• Minerva Neurosciences, Inc.
• Neuraxpharm
• Novartis AG
• Novo Nordisk A/S
• Otsuka Holdings Co Ltd
• Pfizer Inc.
• Polpharma Biologics S.A.
• Rapport Therapeutics, Inc.
• Sage Therapeutics, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Limited
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• TauRx Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SEIZURE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 81. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 84. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 85. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 87. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 89. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 132. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 133. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 135. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 136. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 137. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 139. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 141. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 143. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 146. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 147. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 149. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 151. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023 and is projected to grow to USD 143.11 billion in 2024, with a CAGR of 7.24%, reaching USD 218.45 billion by 2030.

The field of central nervous system therapeutics is rapidly evolving and redefining its approach to treatment, diagnosis, and patient management. Over recent years, advances in research, technology, and clinical methodologies have collectively paved the way for a more personalized and innovative practice in treating complex neurological disorders. Substantial research investments and a heightened understanding of disease mechanisms are driving the development of more targeted therapies that address long-standing challenges in healthcare.

The landscape is marked by emerging translational research and an integration of sophisticated diagnostic tools that enable clinicians and researchers to identify early biomarkers and predict disease trajectories with increasing accuracy. This era of transformation is not merely about incremental refinement; it represents a paradigm shift in how central nervous system disorders are managed, with an emphasis on precision medicine.

Progress in preclinical and clinical studies has accelerated the identification and validation of new molecular targets. As a result, stakeholders are now equipped with enhanced tools to evaluate efficacy and safety across diverse patient populations, ensuring that therapeutic solutions are not only effective but also well tailored to individual needs. This introduction sets the stage for understanding the multifaceted developments that are transforming CNS therapeutics worldwide.

Transformative Shifts Reshaping the CNS Therapeutics Landscape

Recent years have witnessed a wave of transformative shifts across the central nervous system therapeutics landscape, driven by groundbreaking innovations in drug development, regulatory reforms, and strategic market dynamics. The integration of advanced data analytics and genomics has accelerated the identification of novel therapeutic targets, enabling more nuanced approaches to treatment that were once considered the realm of possibility only in the future.

Stakeholders in this sector have experienced a significant transformation as the boundaries between clinical research and real-world evidence blur. This synergy has fostered a collaborative environment wherein academic institutions, biotechnology firms, and pharmaceutical companies work jointly to quicken the pace from discovery to patient delivery. Such partnerships are not only reducing the time-to-market for promising innovations but are also infusing the industry with fresh perspectives on tackling neurological disorders.

In parallel, digital transformation has spurred the adoption of artificial intelligence and machine learning techniques for drug discovery and patient monitoring. This evolution supports more accurate predictive modeling, enhances clinical trial designs, and optimizes patient stratification, ultimately leading to more effective and safer treatments. Regulatory agencies globally are also evolving, providing accelerated pathways and flexible frameworks to ensure that new therapies, once proved safe and efficacious, can be rapidly integrated into clinical practice.

Moreover, the rise in personalized medicine underscores a burgeoning shift from the traditional one-size-fits-all approach toward more patient-specific interventions. These transformative trends are reshaping market dynamics and reorienting strategies, establishing a robust foundation for the next generation of CNS therapeutics.

Key Segmentation Insights Shaping Market Strategies

A detailed examination of market segmentation unveils critical insights that steer strategic decision-making in the domain of CNS therapeutics. A primary segmentation assessment based on disorders provides a comprehensive view of the market where different neurological conditions are stratified into distinct categories. The market is analyzed based on epileptic disorders, neurodegenerative diseases, pain management, and psychiatric disorders. Within epileptic disorders, the focus is further refined to delineate between epilepsy and seizure disorders. In the area of neurodegenerative diseases, attention is given to Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. Similarly, pain management is dissected into acute pain, chronic pain, and neuropathic pain while psychiatric disorders encompass anxiety disorders, bipolar disorder, depression, and schizophrenia.

Further segmentation based on drug type divides market analysis into biologics and small molecules. Within the realm of biologics, the investigation extends to gene therapies, monoclonal antibodies, peptides, and stem cell therapies, revealing opportunities and challenges that are unique to each subcategory. Route of administration forms another crucial segmentation dimension where products are categorized as injectable, oral, and transdermal. In the injectable category, evaluation extends to intramuscular, intravenous, and subcutaneous methods, ensuring that delivery mechanisms are optimized for maximum patient compliance and therapeutic effect.

Finally, understanding the market through the lens of end-users-hospitals, research institutes, and specialty clinics-offers valuable perspectives on potential adoption rates and therapeutic impact. This multiplicity of segmentation factors provides a holistic overview, enabling industry stakeholders to tailor their approaches, mitigate risks, and capitalize on emerging opportunities in a highly competitive landscape.

Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.

Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.

Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.

Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Key Regional Trends and Market Opportunities

Geographical variations play an essential role in shaping the landscape of CNS therapeutics. Trends observed across various regions indicate a divergence in market dynamics and investment philosophies. In the Americas, substantial emphasis is placed on advancing innovative treatments and bolstering the integration of digital health technologies within clinical settings. Regulatory environments in this region tend to favor rapid adoption of breakthrough therapies, creating fertile ground for accelerated clinical trials and strategic public-private partnerships.

In regions spanning Europe, the Middle East, and Africa, robust healthcare infrastructures and the availability of skilled professionals have led to the establishment of centers of excellence. These regions focus on adopting evidence-based practices and optimizing patient care protocols. Strategic investments in research facilities, along with supportive government initiatives, contribute to a steady expansion of tailored therapeutic solutions in these diverse territories.

The Asia-Pacific region represents a dynamic and rapidly evolving market where increasing healthcare expenditures and a growing emphasis on life sciences are driving significant research and development activities. A surge in clinical trials aligned with disease prevalence, coupled with an expanding patient base, positions this region as a critical player in the global CNS therapeutics market. Together, these regional insights present a mosaic of opportunities and challenges that necessitate a nuanced strategy, tailored to the regulatory, economic, and socio-cultural specificities of each market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Influential Market Players and Competitive Dynamics

An in-depth analysis of key companies within the CNS therapeutics arena reveals an intensely competitive landscape marked by continual innovation and strategic expansion. Industry giants such as AbbVie Inc., AC Immune SA, and Acadia Pharmaceuticals Inc. have established themselves as pioneers through their relentless focus on research and development. These companies, in collaboration with firms like Acorda Therapeutics, Inc. and Alkermes PLC, have spearheaded numerous clinical trials that underscore a commitment to advancing therapeutic frontiers.

Major players including Amgen Inc., AstraZeneca PLC, Bayer AG, and Biogen Inc. continue to diversify their portfolios by investing in both biologics and small molecule therapies. The competitive environment is further enriched by the contributions of Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, and Cassava Sciences, Inc., which have leveraged emerging technologies to streamline drug discovery and clinical validation processes. Companies such as Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., and Eisai Co. Ltd. remain at the cutting edge by integrating digital tools into their product development strategies, ensuring that delivery methods and therapeutic outcomes are consistently optimized.

Other influential entities, including Eli Lilly and Company, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, have embraced partnerships and collaborative ventures to bridge gaps between research and clinical practice. H. Lundbeck A/S, Intra-Cellular Therapies, Inc., and Ipsen S.A. have driven innovation through targeted investments in precision medicine, while stalwarts such as Johnson & Johnson Services, Inc., Lupin Limited, and MapLight Therapeutics, Inc. foster a culture of continuous improvement. The landscape is further defined by contributions from Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., and Polpharma Biologics S.A. with final strategic inputs from Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A. These companies collectively shape competitive dynamics and drive forward the evolution of CNS therapeutics on a global scale.

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A.. Actionable Recommendations for Industry Leaders

Industry leaders are presented with a unique opportunity to capitalize on the rapid advancements within CNS therapeutics through strategic investments and collaborative innovation. It is imperative for decision-makers to enhance R&D pipelines by focusing on evidence-based outcomes and leveraging cutting-edge technologies. Prioritizing precision medicine initiatives and investing in biomarker research can yield substantial benefits by enabling early diagnosis and tailored treatment plans.

Furthermore, fostering partnerships between academia, biotechnology firms, and healthcare providers is key to navigating the complexities of central nervous system disorders. Collaborative research can lead to the shared development of robust clinical data, reducing the uncertainty that accompanies novel therapeutic discoveries. Emphasis should also be placed on diversifying clinical trial portfolios to encompass a broad spectrum of patient demographics and regional considerations, thereby ensuring that therapies are adaptable to varying market needs.

Leaders should explore opportunities to integrate digital health solutions, including artificial intelligence and machine learning, to enhance patient monitoring and streamline regulatory submissions. By adopting these actionable recommendations, industry players can mitigate risk, improve market responsiveness, and accelerate the delivery of innovative CNS therapies to the global patient community.

Conclusion: A Vision for the Future of CNS Therapeutics

In summary, the current phase in central nervous system therapeutics is defined by transformative innovations and collaborative endeavors that promise to reshape treatment paradigms. Through an integrated approach combining cutting-edge research, dynamic segmentation analysis, and regional market insights, stakeholders are well positioned to navigate an increasingly complex therapeutic landscape.

The synthesis of progressive drug development strategies and digital advancements underscores a commitment to precision medicine that is increasingly tailored to the individual needs of patients worldwide. As industry leaders continue to invest in innovative solutions and forge strategic alliances, the future of CNS therapeutics appears poised for substantive breakthroughs. This conclusion encapsulates the vital insights and emerging opportunities that serve as a roadmap for sustained growth and excellence in the field.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
    • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
  • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
  • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
  • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

• 6.1. Introduction
• 6.2. Epileptic Disorders
  • 6.2.1. Epilepsy
  • 6.2.2. Seizure Disorders
• 6.3. Neurodegenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Pain Management
  • 6.4.1. Acute Pain
  • 6.4.2. Chronic Pain
  • 6.4.3. Neuropathic Pain
• 6.5. Psychiatric Disorders
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Bipolar Disorder
  • 6.5.3. Depression
  • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Gene Therapies
  • 7.2.2. Monoclonal Antibodies
  • 7.2.3. Peptides
  • 7.2.4. Stem Cell Therapies
• 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral
• 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Research Institutes
• 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
  • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
  • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
  • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
  • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
  • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
  • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
  • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
  • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
  • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
  • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
  • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
  • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
  • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
  • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. F. Hoffmann-La Roche AG
  • 13.4.2. Bristol-Myers Squibb Company
  • 13.4.3. Lupin Limited
  • 13.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. AC Immune SA
• 3. Acadia Pharmaceuticals Inc.
• 4. Acorda Therapeutics, Inc.
• 5. Alkermes PLC
• 6. Amgen Inc.
• 7. AstraZeneca PLC
• 8. Bayer AG
• 9. Biogen Inc.
• 10. Bristol-Myers Squibb Company
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Cassava Sciences, Inc.
• 13. Cipla Limited
• 14. CNS Pharmaceuticals, Inc.
• 15. Denali Therapeutics Inc.
• 16. Eisai Co. Ltd.
• 17. Eli Lilly and Company
• 18. F. Hoffmann-La Roche AG
• 19. GlaxoSmithKline PLC
• 20. H. Lundbeck A/S
• 21. Intra-Cellular Therapies, Inc.
• 22. Ipsen S.A.
• 23. Johnson & Johnson Services, Inc.
• 24. Lupin Limited
• 25. MapLight Therapeutics, Inc.
• 26. Merck KGaA
• 27. Minerva Neurosciences, Inc.
• 28. Neuraxpharm
• 29. Novartis AG
• 30. Novo Nordisk A/S
• 31. Otsuka Holdings Co Ltd
• 32. Pfizer Inc.
• 33. Polpharma Biologics S.A.
• 34. Rapport Therapeutics, Inc.
• 35. Sage Therapeutics, Inc.
• 36. Sanofi S.A.
• 37. Sun Pharmaceutical Industries Limited
• 38. Supernus Pharmaceuticals, Inc.
• 39. Takeda Pharmaceutical Company Limited
• 40. TauRx Pharmaceuticals Ltd
• 41. Teva Pharmaceutical Industries Ltd.
• 42. UCB S.A.